<DOC>
	<DOCNO>NCT01971658</DOCNO>
	<brief_summary>This phase III , multicenter , prospective clinical benefit , open-label randomize study compare two different treatment : Velcade ( Bortezomib ) Thalidomide Dexamethasone ( VTD ) versus Velcade ( Bortezomib ) Cyclophosphamide Dexamethasone ( VCD ) Induction Treatment prior Autologous Stem Cell Transplantation patient Newly Diagnosed Multiple Myeloma . Eligible patient randomize 2 treatment arm . Each patient receive 4 consecutive 21 day cycle induction treatment either VTD VCD .</brief_summary>
	<brief_title>Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone Induction Treatment Initial Management Multiple Myeloma ( IFM2013-04 )</brief_title>
	<detailed_description>The patient population consist adult men woman confirm diagnosis Multiple Myeloma meet eligibility criterion . They recruit among patient consult investigate centre 's haematology service newly diagnose , symptomatic , untreated multiple myeloma . treatment arm : 1 . Induction therapy : 4 cycle VTD ( 21 day ) VCD 2 . Systematic stem cell harvest cycle 3</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients newly diagnose symptomatic Multiple Myeloma ( MM ) patient 1 . 18 ≤ age &lt; 66 year 2 . Eastern Cooperative Oncology Group Performance Status 0 , 1 2 3 . Patients must eligible Autologous Stem Cell Transplantation 4 . Patients must measurable disease serum Mprotein ≥ 10 g/L and/or urine Mprotein ≥200mg/day 5 . Female patient childbearing potential ( FCBP ) : Must agree medically supervised pregnancy test prior start study every 21 day , include 4 week end study treatment . This apply even patient practice complete continue sexual abstinence . Must agree use able comply effective contraception without interruption , 28 day prior start study drug , study therapy ( include period dose interruption ) , 28 day discontinuation study therapy . 6 . Male Patients : Must agree use condom sexual contact FCBP , throughout study drug therapy , dose interruption one week discontinuation study therapy Must agree donate semen study drug therapy one week discontinuation study therapy 7 . All patient must : Agree abstain donate blood take study drug therapy one week discontinuation study drug therapy Agree share study medication another person . 8 . Patients must capable give informed consent 9 . Patients must affiliate French social security system 1 . Asymptomatic Multiple myeloma 2 . Nonsecretory Multiple myeloma 3 . Proven ALamyloidosis 4 . Age ≥ 66 year old 5 . Prior current systemic therapy Multiple myeloma , include steroid ( except emergency use 4day block dexamethasone randomization , maximum total dose allow 160 mg ) 6 . Radiation therapy 2 week precede randomization 7 . National Cancer Institute grade ≥ 2 peripheral neuropathy 8 . Haemoglobin &lt; 8g/dL 9 . Absolute neutrophil count &lt; 1,000 cell / µL , platelet count &lt; 50,000 cell / µL 10 . Creatinine level &gt; 170 µmol/L require dialysis . 11 . Bilirubin , transaminases GamaGT &gt; 3 UNL ( upper normal limit ) 12 . Positive HIV serology , evidence active Hepatitis B C infection 13 . Severe active infection 14 . Inability comply antithrombotic treatment regimen 15 . A personal medical history severe psychiatric disease 16 . Uncontrolled diabetes contraindicate use highdose dexamethasone 17 . Noncontrolled severe cardiovascular disease ( include myocardial infarction 6 month prior recruitment ) 18 . A personal medical history cancer unless patient without relapse treatment discontinuation &gt; = 5 year ( except basocellular skin cancer situ cervical cancer ) 19 . Use investigational drug 30 day precede randomization 22 Pregnant lactate woman . 23 Adults juridical protection 24 Known suspect hypersensitivity study therapy excipients 25 Necessity vaccination yellow fever live vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Newly Diagnosed</keyword>
</DOC>